To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Diclofenac Sodium gel, 1%
Voltaren® Gel
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Healthy male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of OA of the knee according to the American College of Rheumatology (ACR) criteria.
- OA Symptoms for at least 6 months prior to screening.
- Baseline Western Ontario McMaster Osteoarthritis (WOMAC) pain subscale of > 9 on a 20 point scale for the target knee immediately prior to randomization.
Exclusion Criteria:
- History of OA pain in the contralateral knee requiring medication within 1 year prior to screening.
- History of secondary OA, rheumatoid arthritis, chronic inflammatory disease (e.g., colitis) or fibromyalgia.
- History of gastrointestinal bleeding or peptic ulcer disease.
- Known allergy to aspirin or nonsteroidal anti-inflammatory drug (NSAID).
- Use of anticoagulants, ACE-inhibitors, cyclosporine, diuretics, lithium, or methotrexate prior to 30 days of screening.
- Concomitant use of systemic corticosteroids, topical corticosteroids, or immunosuppressive drugs or their use prior to 30 days of screening.
Sites / Locations
- Glenmark Investigational Site 5
- Glenmark Investigational Site 1
- Glenmark Investigational Site 21
- Glenmark Investigational Site 31
- Glenmark Investigational Site 26
- Glenmark Investigational Site 42
- Glenmark Investigational Site 30
- Glenmark Investigational Site 33
- Glenmark Investigational Site 25
- Glenmark Investigational Site 24
- Glenmark Investigational Site 2
- Glenmark Investigational Site 13
- Glenmark Investigational Site 27
- Glenmark Investigational Site 10
- Glenmark Investigational Site 41
- Glenmark Investigational Site 3
- Glenmark Investigational Site 15
- Glenmark Investigational Site 19
- Glenmark Investigational Site 28
- Glenmark Investigational Site 32
- Glenmark Investigational Site 40
- Glenmark Investigational Site 37
- Glenmark Investigational Site 11
- Glenmark Investigational Site 18
- Glenmark Investigational Site 8
- Glenmark Investigational Site 43
- Glenmark Investigational Site 38
- Glenmark Investigational Site 17
- Glenmark Investigational Site 22
- Glenmark Investigational Site 14
- Glenmark Investigational Site 9
- Glenmark Investigational Site7
- Glenmark Investigational Site 36
- Glenmark Investigational Site 39
- Glenmark Investigational Site 23
- Glenmark Investigational Site 20
- Glenmark Investigational Site 34
- Glenmark Investigational Site 35
- Glenmark Investigational Site 44
- Glenmark Investigational Site 4
- Glenmark Investigational Site 29
- Glenmark Investigational Site 6
- Glenmark Investigational Site 16
- Glenmark Investigational Site12
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Placebo Comparator
Arm Label
Diclofenac Sodium gel, 1%
Voltaren® Gel
Placebo
Arm Description
apply gel to the target knee
apply gel to the target knee
apply gel to the target knee
Outcomes
Primary Outcome Measures
Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee
The total WOMAC Pain Subscale score was determined by summing the individual scores from each of the five questions using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4) comprising the WOMAC Pain Subscale Rating for the Target Knee.
Secondary Outcome Measures
Full Information
NCT ID
NCT02596451
First Posted
November 3, 2015
Last Updated
May 26, 2017
Sponsor
Glenmark Pharmaceuticals Ltd. India
1. Study Identification
Unique Protocol Identification Number
NCT02596451
Brief Title
To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc) in Patients With Osteoarthritis (OA) of the Knee
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Glenmark Pharmaceuticals Ltd. India
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients with Osteoarthritis (OA) of the Knee
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1164 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diclofenac Sodium gel, 1%
Arm Type
Experimental
Arm Description
apply gel to the target knee
Arm Title
Voltaren® Gel
Arm Type
Active Comparator
Arm Description
apply gel to the target knee
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
apply gel to the target knee
Intervention Type
Drug
Intervention Name(s)
Diclofenac Sodium gel, 1%
Intervention Type
Drug
Intervention Name(s)
Voltaren® Gel
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee
Description
The total WOMAC Pain Subscale score was determined by summing the individual scores from each of the five questions using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4) comprising the WOMAC Pain Subscale Rating for the Target Knee.
Time Frame
Baseline and week 4
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy male or non-pregnant female aged ≥ 35 years with a clinical diagnosis of OA of the knee according to the American College of Rheumatology (ACR) criteria.
OA Symptoms for at least 6 months prior to screening.
Baseline Western Ontario McMaster Osteoarthritis (WOMAC) pain subscale of > 9 on a 20 point scale for the target knee immediately prior to randomization.
Exclusion Criteria:
History of OA pain in the contralateral knee requiring medication within 1 year prior to screening.
History of secondary OA, rheumatoid arthritis, chronic inflammatory disease (e.g., colitis) or fibromyalgia.
History of gastrointestinal bleeding or peptic ulcer disease.
Known allergy to aspirin or nonsteroidal anti-inflammatory drug (NSAID).
Use of anticoagulants, ACE-inhibitors, cyclosporine, diuretics, lithium, or methotrexate prior to 30 days of screening.
Concomitant use of systemic corticosteroids, topical corticosteroids, or immunosuppressive drugs or their use prior to 30 days of screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mahesh V Deshpande
Organizational Affiliation
Glenmark Pharmaceuticals Ltd
Official's Role
Study Director
Facility Information:
Facility Name
Glenmark Investigational Site 5
City
Mesa
State/Province
Arizona
Country
United States
Facility Name
Glenmark Investigational Site 1
City
Anaheim
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 21
City
Anaheim
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 31
City
Anaheim
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 26
City
Canoga Park
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 42
City
Carlsbad
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 30
City
Carmichael
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 33
City
Cerritos
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 25
City
El Cajon
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 24
City
La Mesa
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 2
City
Pasadena
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 13
City
Rancho Cucamonga
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 27
City
Sacramento
State/Province
California
Country
United States
Facility Name
Glenmark Investigational Site 10
City
Fort Lauderdale
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 41
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 3
City
Miami Lakes
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 15
City
Miami
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 19
City
Miami
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 28
City
Miami
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 32
City
Miami
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 40
City
Miami
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 37
City
Ormond Beach
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 11
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 18
City
West Palm Beach
State/Province
Florida
Country
United States
Facility Name
Glenmark Investigational Site 8
City
Evanston
State/Province
Illinois
Country
United States
Facility Name
Glenmark Investigational Site 43
City
Newburgh
State/Province
Indiana
Country
United States
Facility Name
Glenmark Investigational Site 38
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
Glenmark Investigational Site 17
City
New Orleans
State/Province
Louisiana
Country
United States
Facility Name
Glenmark Investigational Site 22
City
Saginaw
State/Province
Michigan
Country
United States
Facility Name
Glenmark Investigational Site 14
City
Saint Louis
State/Province
Missouri
Country
United States
Facility Name
Glenmark Investigational Site 9
City
Englewood
State/Province
Ohio
Country
United States
Facility Name
Glenmark Investigational Site7
City
Altoona
State/Province
Pennsylvania
Country
United States
Facility Name
Glenmark Investigational Site 36
City
Knoxville
State/Province
Tennessee
Country
United States
Facility Name
Glenmark Investigational Site 39
City
Nashville
State/Province
Tennessee
Country
United States
Facility Name
Glenmark Investigational Site 23
City
Beaumont
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 20
City
Bryan
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 34
City
Dallas
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 35
City
Houston
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 44
City
Houston
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 4
City
Lampasas
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 29
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 6
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Glenmark Investigational Site 16
City
Charlottesville
State/Province
Virginia
Country
United States
Facility Name
Glenmark Investigational Site12
City
Midlothian
State/Province
Virginia
Country
United States
12. IPD Sharing Statement
Learn more about this trial
To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
We'll reach out to this number within 24 hrs